NCT04827576 2025-05-08
ELEVATELung&UC
Gilead Sciences
Phase 2 Terminated
Clinical Trials
9 trialsNCT04810208 2021-12-30
Intratumoural Injection of a Novel NanoZolidĀ®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
Lidds AB
Phase 1 Terminated
NCT04360317 2020-04-24
Safety of the Combination of SH003 and Docetaxel in Patients With Solid Cancer
Kyunghee University Medical Center
Phase 1 Unknown
NCT02963168 2019-10-17
A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies
Athenex, Inc.
Phase 1 Unknown
NCT02490475 2017-05-17
A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02274610 2017-05-01
DOPNP201
Samyang Biopharmaceuticals Corporation
Phase 1 Completed
NCT01336582 2012-12-21
Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer
Samyang Biopharmaceuticals Corporation
Phase 1 Completed
NCT00251407 2012-08-09
Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00888108 2012-05-22
Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer
Abbott
Phase 1 Completed